Respiratory syncytial virus (RSV) causes severe respiratory disease in calves and human infants. In response to outbreaks, formalin inactivated (FI)-RSV vaccines were developed and found to exacerbate disease following a live RSV infection. We have reproduced vaccination induced disease enhancement in calves and screened various antibody isotypes in bronchoalveolar lavage fluid (BALF) from two studies: one with disease enhancement and another where moderate protection resulted from FI-bovine RSV (BRSV) vaccination. Semi-protected vaccinated calves produced BRSV-specific BALF IgG1, but not IgA and IgG2 prior to infection; whereas, calves with enhanced disease failed to develop BRSV-specific IgG1 in BALF. Ultimately, the formulation and delivery of RSV vaccines influences protective antibody levels in respiratory secretions.
ASJC Scopus subject areas
- Infectious Diseases
- Public Health, Environmental and Occupational Health